Alcyomics offers human in vitro (lab-based) pre-clinical safety testing to ensure drug safety and efficacy before first administration into man.
3D Tissue Models 2017: Drug Discovery and Development
Monday 28th – Wednesday 30th August 2017, Revere Hotel Boston, Boston, MA.
Alcyomics will be attending the second annual 3D Tissue Models summit which showcases the latest advances in bioengineering and 3D cell culturing with the aim to strengthen the predictability and interpretation of model-based research within preclinical development.
Asif Tulah will be presenting a scientific poster titled: ‘Development of a full-thickness 3D autologous skin equivalent model (Skimune®3D) to determine immunogenicity of therapeutics.’ This will be a first introduction tot the autologous 3D skin equivalent model that Alcyomics have developed, with a full launch of this model expected later in the year.
The 3D Tissue Models summit opens a perfect opportunity to see how 3D tissue culture models such as Skimune®3D can aid the drug discovery process through greater accuracy in safety measurements. For more information on this event, visit http://3d-tissuemodels.com/
Abstract: Development of a full-thickness 3D autologous skin equivalent model (Skimune®3D) to determine immunogenicity of therapeutics
Asif S. Tulah PhD, Shaheda S. Ahmed PhD and Anne M Dickinson PhD
Alcyomics Ltd, Newcastle upon Tyne, United Kingdom
Tenth World Congress on Alternative and Animal Use in the Life Sciences
Sunday 20th – Thursday 24th August 2017, Washington State Convention Centre, Seattle, Washington, USA
Alcyomics will be attending the Tenth World Congress on Alternative and Animal use in the Life Sciences. The theme of this year’s conference is “The Three R’s in Action” and is promised to be a cutting edge scientific meeting, focused on the latest cutting edge technologies that aim for the reduction and replacement of animals, which is where our portfolio of novel assays come in!
Alcyomics will be attending the meeting to introduce our range of human in vitro Skimune® assays which are completely free of animal components. In our tests we use, skin and blood from healthy human volunteers. At the meeting we will be addressing, the benefits Alcyomics services offers the Pharmaceutical, Chemical and Cosmetic industries.
Louis Bibby, one of our young researchers will be presenting a poster titled: ‘Predicting adverse immune reactions to biopharmaceuticals using the Skimune® technology, a platform of novel in vitro skin explant tests’. The poster will be presented within the Innovative Models for Safety and Efficacy stream, this poster will show how we can use the Skimune®Mab assay for preclinical prediction of adverse reactions to biological drugs using our human in vitro tests
We will also be giving an oral presentation on Thursday (24th August) at 11:30 titled: An in vitro human skin test for assessing allergy and sensitization. This will be presented in the New Advances in Models for Skin stream, where we will discuss our existing portfolio of skin assays and introduce exciting new developments we’ve made with our new Skimune® 3D model.
For more information on the WC10 conference visit: http://wc10seattle.org/2017/home.aspx or catch up with us in Seattle. If you would like to discuss our assays in more detail Louis Bibby would be happy to arrange 1:1 meetings during his visit in Seattle. Please contact him on email@example.com
Once again Alcyomics will be attending the PEGS Summit to be held next week in Boston.
Whilst at the event we will be running two poster sessions, in addition to Dr Ahmed giving a talk on Monday 1st May within the Cellular Therapies Stream. The talk is titled Human in vitro Skin Explant Assays for Predicting Immunotoxicity of Drugs and Cellular Therapies. Dr Ahmed will discuss how Skimune® can be used as a screening service for biological drugs, as well as small molecule drugs to predict immunotoxicity, and also cellular therapies.
Dr Ahmed will run a poster session on Thursday to cover the topic once more.
On Monday Louis Bibby will be running a poster session titled Predicting Adverse Immune Reactions to Biopharmaceuticals Using Skimune®, a Human in vitro Skin Explant Test: A Novel Tool for Biopharmaceutical Research & Development.
The poster gives detail of the Skimune® Mab assay and how it can be used for predicting adverse immune reactions to biological drugs, as well as Skimune® 3D model and how that can also be used in the same manner.
For more information on the PEGS Summit please visit http://www.pegsummit.com/ and if you are in the area, please come along to discuss any requirements that you may have or just to find out more about the services that we can offer.
Alcyomics will be attending this workshop co-organised by the NC3Rs, SPS and Coventry University. The event aims to provide discussion on how best to support and enable the use of human tissues in safety testing and will be attended by researchers from SMEs and the pharmaceutical industry as well as academia.
We will present a research poster highlighting Alcyomics’ in vitro skin explant assays (Skimune®) and 3D autologous skin equivalent model (Skimune®3D) to assess the safety, efficacy and dose response to biopharmaceuticals, cosmetics and chemicals.
The event will be held at Coventry University on Wednesday 3rd May 2017. Please see the website for more details http://www.nc3rs.org.uk/events/nc3rssafety-pharmacology-society-regional-meeting-use-human-tissues-safety-assessment